Online inquiry

IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3424MR)

This product GTTS-WQ3424MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets HGF gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000601.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3082
UniProt ID P14210
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3424MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ541MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 4D5-8
GTTS-WQ7155MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FG-3019
GTTS-WQ14017MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ4500MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ1943MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ13692MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RC48
GTTS-WQ197MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ7870MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK-2398852
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW